Permanent pacing after cardiac transplantation

SIR,—Scott et al reported that only a few patients given a permanent pacemaker subsequently needed long-term rate support.1 This accords with our experience and that of other groups.2 We recently learned, however, that what appears to be transient sinus node dysfunction may not be.1 Only one of six patients fitted with AADR pacemakers that allowed for follow-up determination of sinus node recovery time also had a normal recovery phenomenon. One patient who had been in slow junctional escape rhythm until late in the postoperative period had permanent pacemaker placement before discharge. One year later he was in sinus rhythm at a rate of about 85 beats/min and a Holter recording showed that he was overriding the pacemaker most of the day. This accorded with the findings of Scott et al and Markewitz et al.2 The recovery phenomenon, however, was grossly abnormal with a postspacing pause of more than 4 s during which he had symptoms.3 While it is clear that an abnormal recovery time is not in itself an indication for pacemaker placement, as we stated in our original version of our paper, this may not be true in a patient with a cardiac transplant who has had symptoms. Though much is known about the incidence of sinus node dysfunction after cardiac transplantation, the actual incidence of symptoms remains unknown and may be underestimated because of the low threshold for postoperative pacemaker placement. In our series of 90 patients three recipients had to be given a pacemaker.4 Sinus node deficiency had been evident in these patients but its severity had been underestimated.4 We want to draw attention to the fact that late restoration of sinus rhythm in a patient with a heart transplant may indicate reversion to a latent type of sick sinus syndrome rather than normalisation of sinus node function. These patients may still be liable to severe symptoms.

GOTTFRIED HEINZ
Department of Internal Medicine II, Division of Cardiology, University Vienna, Vienna, Austria

1 Scott CD, McComb JM, Dark JH, Beaton RS. Permanent pacing after cardiac transplantation. Br Heart J1993;69:399–403.


Are streptokinase antibodies clinically important?

SIR,—We read with interest the editorial by Dr M B Buchalter (1993;70:101–2) on the clinical significance of antistreptokinase antibodies and neutralisation titres. He suggests that it would seem sensible not to re-administer streptokinase until it is proven that these antibodies are of no clinical significance. The editorial concentrated on the persistence of antistreptokinase antibodies for at least four years after initial exposure to streptokinase.

A considerable number of patients re-infarct in the first few days after the initial infarction.1 Buchalter showed that antistreptokinase antibodies do not rise above pretreatment values until day four after the administration of streptokinase.2 They did not measure neutralisation titres. We looked at the early immunoassay of streptokinase antibodies and neutralisation titres after streptokinase administration and found no rise in the neutralisation titres until day four after streptokinase.3 Therefore there may be an early window when streptokinase can be re-administered. These observations suggest that re-administration of streptokinase is appropriate during the three days after an initial dose of streptokinase or anistreplase. This has important financial implications in view of the price difference between streptokinase and non-antigenic thrombolytic agents.

H S LEE
S J CROSS
K JENNINGS
Department of Cardiology, Aberdeen Royal Infirmary, Aberdeen AB2 2ZB


3 Lee HS, Cross SJ, Davidson R, Reid T, Jennings K. Raised levels of antistreptokinase antibodies and neutralisation titres from four days to 54 months after administration of streptokinase or anistreplase. Eur Heart J1993;14:94–9.

This letter was shown to the author, who replies as follows:

SIR,—I agree with Lee et al that as streptokinase antibodies do not seem to rise until day 4 after streptokinase administration, repeating the streptokinase before this time is likely to be safe and effective.

M BUCHALTER
Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff CF4 4XX

Spontaneous ventricular defibrillation

SIR,—We read with pleasure the article of van Hemel and Kingma on self-terminating ventricular fibrillation.1 They suggest that transient ventricular fibrillation is unusual and presumably occurs when there is a rapid and complete re-establishment of pre-existing normal electrophysiological properties. In the myocardium, they recorded the existence of transient ventricular fibrillation to the rapid electrophysiological improvement during the dynamic process of reperfusion.

We have worked on transient ventricular fibrillation for more than a decade and we want to question these two points. Firstly, transient ventricular fibrillation is not unusual. It has been reported in various mammals2 and it is not so rare clinically.3 Secondly, during ventricular fibrillation there is no coronary circulation and reperfusion stops when ventricular fibrillation starts. For this reason the suggestion that an "increase in organisation of ventricular fibrillation into ventricular flutter" is a result of rapid electrophysiological improvement during the dynamic process of reperfusion (which does not exist during ventricular fibrillation) seems unlikely. Because reperfusion cannot explain the synchronisation of ventricular fibrillation that takes place over time and leads to spontaneous defibrillation we propose an alternative explanation.

On the basis of our experimental studies,4 we have hypothesised that transient ventricular fibrillation requires the maintenance of a high sympathetic and low parasympathetic level during ventricular fibrillation. This hypothesis was based on results obtained in studies5 showing that transient ventricular fibrillation is a normal feature in mammals that have predominantly sympathetic cardiac autoregulation whereas sustained ventricular fibrillation occurs in those mammals that have predominantly parasympathetic autoregulation.6 Moreover, it has been shown that sustained ventricular fibrillation can be transformed into transient ventricular fibrillation either by pretreatment with various compounds that increase the cardiac catecholamine concentration during ventricular fibrillation7 or by intracoronary administration of adrenaline during ventricular fibrillation.8

Our hypothesis suggests that a high cardiac catecholamine concentration improves intercellular coupling and intercellular synchronisation, leading different myocardial cells to fibrillate coordinately.9 This sympathetically induced synchronisation organises ventricular fibrillation with ventricular flutter and leads to subsequent spontaneous restoration of the sinus rhythm.

According to this assumption, the phenomenon described by van Hemel and Kingma can be related to the increases in sympathetic activity induced by ventricular fibrillation which increase the cardiac concentration of catecholamines for time. In a heart without structural heart disease, this increase in catecholamine concentration organises the configuration of the unsynchronised ventricular fibrillation into more organised "coarse" ventricular fibrillation, which in some cases terminates spontaneously.

The various problems involved in transient ventricular fibrillation were discussed.
Are streptokinase antibodies clinically important?

H S Lee, S J Cross, K Jennings and M Buchalter

Br Heart J 1993 70: 590
doi: 10.1136/hrt.70.6.590-a

Updated information and services can be found at:
http://heart.bmj.com/content/70/6/590.2.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/